Navigation Links
Oligomerix Awarded Phase IIB Grant From the NIH to Discover Drugs that Inhibit Alzheimer's Disease Progression
Date:9/10/2013

on Biomedical Science and Technology Park at Columbia University Medical Center and is carrying out its in vivo studies at New York Medical College.  The Company is seeking strategic partners to help accelerate these exciting programs.  For more information, visit www.oligomerix.com.

Certain matters described in this news release may be forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risk of dependence on market growth, competition and dependence on government agencies and other third parties for funding contract research and services.

CONTACTS:
Oligomerix, Inc.
Jack Pasini
Chief Commercial Officer
917-912-4088
jpasini@oligomerix.com

Tiberend Strategic Advisors, Inc.
Andrew Mielach
212-375-2694
amielach@tiberend.com


'/>"/>
SOURCE Oligomerix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. NovelMed Awarded NIH Fast Track SBIR Grant for $1.43 Million to Advance Development of its Anti-Complement Antibody for Orphan Disease
2. Carolina Piedmont Capital Awarded VOSB Certification
3. B. Braun Awarded Premier Healthcare Alliance Contract for Dual-Source IV
4. Novan Awarded $7.8 Million Contract by BARDA to Develop a Medical Countermeasure for Thermal Burns
5. Fountain Valley Regional Medical Center Becomes Orange Countys First Hospital Awarded Advanced Certification In Inpatient Diabetes Care
6. aTyr Pharma Awarded Two Patents from USPTO to Support Development of New Therapeutics Based on Physiocrine Biology
7. Arisaph Pharmaceuticals Awarded Phase I STTR Grant To Develop Small Molecule Immune Modulators
8. All Time Medical awarded a Google Trusted Store badge.
9. Dynamic Healthcare Services Awarded Two Oxygen Equipment Competitive Bidding Contracts
10. Instrumentation Laboratory Awarded Premier Healthcare Alliance Contract For Hemostasis Product Line
11. Great Lakes NeuroTechnologies Awarded Patent For Technology To Treat Parkinsons Disease With Brain Stimulation During Sleep
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... its Symphony® CGM System as a non-invasive, wireless continuous ... Doman , Executive Chairman and Interim CEO of Echo ... Tenth Annual Equity Conference. Mr. Doman ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... - India Drug Forecast and Market Analysis ... PharmaPoint: Atopic Dermatitis - India ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a leading ... of severely obese patients, today announced initial results ... selective inhibitor of methionine aminopeptidase 2 (MetAP2), in ... of genetic obesity.  These results showed improvements in ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... Calif., May 5, 2011 Rigel Pharmaceuticals, Inc. (Nasdaq: ... chief financial officer, is scheduled to present a company overview ... in Las Vegas on Tuesday, May 10th at 10:00 a.m. ... The presentation will be webcast live and can be accessed ...
... May 5, 2011 Rochester Medical Corporation (NASDAQ: ... ended March 31, 2011. The Company reported record ... for the second quarter of last year.  It also reported ... to net loss of ($351,000) or ($0.03) per diluted share ...
Cached Medicine Technology:Rochester Medical Reports Second Quarter Results 2Rochester Medical Reports Second Quarter Results 3Rochester Medical Reports Second Quarter Results 4Rochester Medical Reports Second Quarter Results 5Rochester Medical Reports Second Quarter Results 6Rochester Medical Reports Second Quarter Results 7Rochester Medical Reports Second Quarter Results 8Rochester Medical Reports Second Quarter Results 9Rochester Medical Reports Second Quarter Results 10
(Date:4/17/2014)... lost its status as the leading weapon against the ... life, with new research indicating it simply needs to ... use of the cheap anti-malarial drug chloroquine in treating ... of more than half a million people each year ... has developed resistance to chloroquine, but research carried out ...
(Date:4/16/2014)... the embryo. It begins as a glob of identical cells ... the cells of our lungs, muscles, nerves and all the ... feat of reverse tissue engineering, Stanford University researchers have begun ... to proliferate and transform into all of the specialized cells ...
(Date:4/16/2014)... 16, 2014): Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced ... of CDX-1401 in solid tumors, including long-term patient follow-up, ... (Vol 6 Issue 232). The data demonstrate robust antibody ... in patients with very advanced cancers and suggest that ...
(Date:4/16/2014)... April 16, 2014 According to a new ... average-risk patients with one to two small polyps are ... cases. This may be an appropriate target for quality ... to quantify adherence to guidelines for timing of repeat ...
(Date:4/15/2014)... , Cases of diabetes and pre-diabetes in the United States ... Johns Hopkins Bloomberg School of Public Health, with obesity apparently ... the burden of the disease has not hit all groups ... the elderly. , According to new research reported in the ...
Breaking Medicine News(10 mins):Health News:Scientists find new way to fight malaria drug resistance 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 2Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 3Health News:Pre-diabetes and diabetes nearly double over the past 2 decades 2
... , ... ... ... ...
... ... ... , ... , , ...
... of the blood or hematopoietic system derive from stem cell ... to all the different kinds of blood cells equally, said ... a report that appears in the current issue of the ... "While previous reports in journals have hinted at ...
... preparation (ICCBco) in the treatment of lung lesions ... experimental animal model, a research group in China ... pathological changes and pathological effect mechanism of expression ... of portal hypertensive rabbits with schistosomiasis. ...
... In tests, novel immunotherapy appears to combat mesothelioma tumors ... vaccine for the asbestos-related cancer mesothelioma is safe, according ... tested the vaccine -- which infuses a patient,s own ... on 10 patients and found that it induced an ...
... , ... ... ... , ...
Cached Medicine News:Health News:'Less Is More' with the Innovation of Avemar(R) Fermented Wheat Germ Extract 2Health News:'Less Is More' with the Innovation of Avemar(R) Fermented Wheat Germ Extract 3Health News:'Less Is More' with the Innovation of Avemar(R) Fermented Wheat Germ Extract 4Health News:'Less Is More' with the Innovation of Avemar(R) Fermented Wheat Germ Extract 5Health News:Studies Detail Possible Benefits of omega-3 Fatty Acids for Dogs With Arthritis 2Health News:Studies Detail Possible Benefits of omega-3 Fatty Acids for Dogs With Arthritis 3Health News:Studies Detail Possible Benefits of omega-3 Fatty Acids for Dogs With Arthritis 4Health News:Theory of single stem cell for blood components challenged 2Health News:Treatment of portal hypertensive pulmonary lesions induced by schistosomiasis 2Health News:Vaccine for Asbestos-Related Cancer Looks Safe 2Health News:Hill-Rom Announces Second Quarter 2010 Dividend 2
... The PalmScan A2000 A-Scan [i.e., PalmScan A2000] ... biometer, which incorporates A-mode pulsed-echo ultrasound,technology, and ... the axial length (AL), anterior,chamber depth (ACD), ... This PalmScan A2000,device is also intended for ...
... TOX/See™ is a 1-step, hand-held, point-of-care device for ... in human urine. The TOX/See device can ... abused drugs in 3 to 8 minutes and ... TOX/See cassette is individually packaged to maximize convenience ...
... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
Medicine Products: